Eli Lilly and Company - AI Stock Analysis

Analysis generated January 22, 2026

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company is renowned for its innovative approach to drug discovery and development. With a rich history of developing groundbreaking treatments, Eli Lilly focuses on providing medicines in areas such as oncology, immunology, neuroscience, and diabetes. This company continues to be a significant player in the pharmaceutical industry, with a strong portfolio of patents and a robust pipeline of experimental medicines.

Fundamental Analysis

The revenue for the last quarter was $17.6 billion, indicating a robust growth of 13.13% from the previous quarter. Notably, compared to the same quarter last year, the revenue has surged by 53.87%, highlighting positive year-over-year growth.

The net income for the last quarter stood at $5.58 billion, which is a slight decrease of 1.38% from the previous quarter. However, compared to the same quarter last year, there's a remarkable increase of 475.34%, signaling significant year-over-year progress. Interestingly, the EBITDA for the last quarter was $7.88 billion, up by 5.04% from the previous quarter and an astonishing 250.64% increase year-over-year, indicating the company's ability to generate profitable earnings before interest, taxes, depreciation, and amortization.

One potential area of concern could be the company's P/E ratio, which stands at 51.02. This ratio is commonly considered high, potentially suggesting the stock might be overvalued, leading to a bearish outlook. Furthermore, there have been instances of company insiders selling their stock, which could be a bearish signal indicating a potential decline in future stock prices.

Technical Analysis

Today's stock price is $1,091.23, which represents an increase of 1.37% compared to a month ago, indicating a positive short-term trend. On a longer time horizon, compared to a year ago, the stock price has surged by 43.40%, suggesting a favorable long-term trend. The overall trend is bullish.

The stock's Simple Moving Average (SMA10) is $1,054.81, marginally higher than the previous SMA10 of $1,053.79, indicating a subtle but positive trend in price movement. On the other hand, the Relative Strength Index (RSI) is 87.7, which could indicate that the stock is potentially overbought, pointing to a bearish condition.

Alternative Data Analysis

According to job postings and employee sentiment data from popular job boards, Eli Lilly and Company has 890 open positions, with the number remaining stable over the past few months, suggesting a solid and stable workforce. Moreover, about 83% of employees have a positive business outlook, which is encouraging and demonstrates internal confidence in the company's future.

In terms of customer engagement, Eli Lilly and Company recorded an estimated 8.1 million visitors to their webpage, with this number increasing by 18% over the last few months—a bullish sign indicating potential growth in customer acquisition. The company also saw a 16% increase in Instagram followers, totaling 61,000, showing enhanced interest in social media presence. Conversely, the number of Twitter followers decreased by 1% to 140,000, indicating a slight decline in interest on that platform.

Moreover, AltIndex's AI score, which assesses stocks based on fundamental, technical, and alternative data analysis, gives Eli Lilly and Company a score of 66, signaling a buy recommendation.

Conclusion

In conclusion, Eli Lilly and Company showcases robust financial health, evident from its significant year-over-year growth in revenue, net income, and EBITDA. The technical indicators suggest a mostly bullish trend despite the overbought RSI conditions. Alternative data also supports a positive outlook with stable job postings, high employee sentiment, and increasing online engagement. However, keeping in mind the high P/E ratio and insider sell-offs, some caution is warranted. Based on the comprehensive analysis, Eli Lilly and Company presents a promising investment opportunity with an optimistic growth prospect.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.